

DAVID RICHARD DODDS

4686 DRUIDS GLEN
MANLIUS, NEW YORK 13104
USA
www.techdiligence.net

DESK: 315 682 3977
MOBILE: 315 884 3703
FAX: 315 663 3020
daviddodds@alltel.net

SUMMARY

Established successful interdisciplinary consultancy serving small/start-up pharma, biotech, and industrial biotech companies. Directed multi-disciplinary process development groups in major pharmaceutical corporations. Built new, practical technology within both small company and large corporate environments. Extensive project management experience covering process chemistry, molecular biology, biotransformations & biocatalysis, plus fermentation of natural products and recombinant enzymes. Extensive experience under GMP; CMC support for IND & NDA filings. Extensive speaking, patent and publication record. Experience as technical member on due-diligence teams. Expert witness experience and extensive industrial and academic network. Service as North American Editor of international journal and as Chairs of international symposia on biocatalysis. United States and Canadian citizenships.

APPOINTMENTS

- 2006 - CSO, zuSyn Inc., (zuChem subsidiary)
- 2005 - Sr. Advisor, Rondaxe Pharma LLC
- 2003-06 Technical Advisor/Manager, Michigan Biotechnology Institute (MBI)
- 2002 - zuChem Scientific Advisory Board
- 2002 - Codexis Industrial Advisory Board
- 2002 - President, Dodds & Associates LLC
- 2000-01 Director, Fermentation & Biocatalysis Development, Bristol-Myers Squibb
- 1999-00 Associate Director, Enzyme Development
- 1998-02 North American Editor, *Journal of Molecular Catalysis B: Enzymatic*
- 1991-99 Manager, Biotransformations Group, Schering-Plough Research Institute
- 1986-91 Sr. Protein Biochemist, Sepracor Inc.

EDUCATION

- 1984-86 MRC Post-doctoral Fellow in Molecular Biology, University of Colorado, Boulder
Prof. Marvin H. Caruthers
- 1979-84 Ph.D. Organic Synthesis, University of Toronto
Prof. J. Bryan Jones
- 1977-79 M.Sc. Biological Chemistry, University of Toronto
- 1973-77 B.Sc. Biochemistry, Trinity College, University of Toronto

OTHER ACCOMPLISHMENTS

- 10 issued patents; numerous foreign filings
- 24 reviewed publications; editor of two-volume compendium
- Multiple invited conference talks; numerous poster presentations
- Chair and fundraising for international conferences

PROFESSIONAL EXPERIENCE

DODDS & ASSOCIATES LLC

Founded Dodds & Associates in 2002 to provide strategic technical planning and project management to the pharmaceutical, biotech, industrial biotech, and chemical industries. D&A targets small and start-up companies needing interdisciplinary experience at a senior level to establish technical strategy, write grant applications, and to provide project management at contract sites when in-house facilities do not yet exist. Executed contracts with over 15 clients since 2002; client references available.

Completed and current projects include:

- Service on technical Advisory Boards; technical presentations to Corporate Board and to investors
- Intellectual property review and strategy, technical assessment and due-diligence
- Project Management:
 - process review, development, and scale-up for both pharma and non-pharma projects, including industrial biotechnology for production of commodity, non-fuel chemicals from biomass
 - contractor selection, site visits for contract compliance, project reporting & oversight
 - CMC support for IND & NDA, batchrecord drafting and review for GMP production
- Interim technical executive for small entities and start-ups
- Expert witness experience & service

BRISTOL-MYERS SQUIBB

Invited to BMS in 1999 to lead a new group of 50 scientists organized into chemical process development, molecular biology, fermentation development, and GMP analytical functions. Managed \$4 million in annual operating and capital budgets.

Developed chiral chemical processes, plus fermentations for natural products, enzyme production, and biocatalysis. Projects included fermentation and isolation of natural products, establishing culture banks and seed train for large-scale fermentations supplying clinical material under GMP; plant cell-culture production of Taxol®; biocatalysis via whole cell, resting biomass, and isolated enzymes; screening, cloning, chemical gene synthesis, expression and immobilization of enzymes, plus all necessary process organic chemistry.

Reviewed all external technology presented to BMS for paclitaxel production for corporate response. Renewed and managed multi-million dollar taxane project with external company.

SCHERING-PLOUGH RESEARCH INSTITUTE

Invited to SPRI in 1991 to establish a new group to develop biocatalysis for more efficient and cost-effective syntheses of APIs. The Group formally reported to both Biotechnology and Chemical Development organizations, and had total of 37 public releases and 13 patent disclosures (6 issued, one kept secret).

Introduced a range of biological catalytic activities, which were applied at scales ranging from the small-scale lab synthesis of metabolites, to pilot plant processes providing 100s of kgs of intermediates for the synthesis of clinical material. Established enzyme process now used commercially in synthesis of Posaconazole®. Established processes using isolated enzymes under both aqueous and non-aqueous conditions, using resting biomass under non-physiological conditions, and classical submerged fermentations.

SEPRACOR

Managed the biocatalysis research, reporting to the VP R&D. Mission was to create commercial opportunities for Sepracor's core membrane technology by identifying technical opportunities for bioreactor processes. Inventor of enzyme process for resolution of Diltiazem® intermediate; process used commercially. Synthesized unique class of ester substrates unusually susceptible to highly enantiospecific hydrolysis by proteolytic enzymes, and which also permitted unusual transesterification reactions.